Fertil Steril. 2025 Nov 1;124(5 Pt 1):878-892. doi: 10.1016/j.fertnstert.2025.05.139.
ABSTRACT
Preimplantation genetic testing for aneuploidy (PGT-A) is commonly used in in vitro fertilization to improve embryo selection and treatment efficiency. Current evidence does not suggest significant obstetric or neonatal risks associated with PGT-A as it is practiced today. However, interpretation is limited by substantial variability between studies and potential confounding factors, including differences in patient characteristics between those undergoing preimplantation genetic testing and standard in vitro fertilization. Additionally, assessing rare and long-term health outcomes requires large study populations and long follow-up periods. Until more conclusive evidence is available, thorough patient counseling is important-clearly communicating the potential benefits, risks, and uncertainties of PGT-A, and ongoing high-quality, prospective safety research is essential to better define its safety and effectiveness.
PMID:41106956 | DOI:10.1016/j.fertnstert.2025.05.139
